Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. - Wikidata - awgldk - TriplyDB

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

http://www.wikidata.org/entity/Q37394083

about

Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination Circular RNAs in heart failure.Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.Sacubitril-valsartan: novel therapy for heart failure.Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial.Angiotensin Receptor-Neprilysin Inhibition.Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study.Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges.Insights into implementation of sacubitril/valsartan into clinical practice.Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.Publishing in a heart failure journal-where lies the scientific interest?Integrating New Pharmacologic Agents into Heart Failure Care: Role of Heart Failure Practice Guidelines in Meeting This Challenge.Combined Angiotensin Receptor-Neprilysin Inhibitors Improve Cardiac and Vascular Function Via Increased NO Bioavailability in Heart Failure.[Acute and chronic heart failure].[The new ESC Guidelines for acute and chronic heart failure 2016].Real-world dosing of evidence-based medications for heart failure: embracing guideline recommendations and clinical judgement.October 2016 at a glance: treatment of heart failure.Sacubitril/Valsartan (LCZ696) in Heart Failure

P2860

Q37597972-9EA9B5D3-9ECD-4CD7-B6B5-3C6541036DFA Q38739402-CF80A599-6665-4DAE-8175-372507BF7665 Q39192295-A38A6E98-4038-4730-908E-9289491B1F0A Q41148299-5F4F3E1A-0EAB-49F5-B14E-26DE4122CA48 Q46132135-B4864064-44E9-4094-8FB8-33A488A8ACF1 Q46770238-4A3C9F72-FB8C-4CC4-B9AD-236415F82200 Q47700110-F1DA7F83-CB87-49FA-A11C-B23AA8613951 Q49586918-5DA5BE60-8C9E-4D7D-89B3-AE467E1C7335 Q49718855-A9B45277-2F99-4FDC-B90F-AEA56CF02786 Q49848555-305AFFCC-1882-40C5-8AA9-9A4CCCE8C5B4 Q50048824-CD0D1BDC-9F5A-445F-9C04-2CF4B5D9CA42 Q50660284-47BD1D6E-2592-46C6-988E-81AF3E8E2FF3 Q52675558-190BAC82-2FB2-40DC-B01E-8547A5CC333F Q52821448-D07E01F4-3DC8-49E1-8A8D-CF6061D4E574 Q52844963-226D26DC-5EA0-4E1C-BA6C-A41D6D67C059 Q53121367-D1509075-3022-42C2-9AD8-1FAD51D50B25 Q54575009-4853E084-6949-4079-BCF1-32B891B8AA04 Q57396137-3A5E4AF7-6AB0-41B5-8FC3-D2588F525AB3

P2860

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

http://www.wikidata.org/entity/Q37394083

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@en

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@nl

type

label

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@en

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@nl

prefLabel

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@en

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@nl

P1433

Q37394083-1C18B64F-8E43-4988-90B9-7195B240AE28

P1476

Q37394083-181CDEFB-0237-4F07-8750-80452ACAB3E8

P2093

Q37394083-15F7B817-5ED2-4C70-BC35-E66AA5B7283E

Q37394083-4E3767B6-E71F-405D-9267-0760D42F828E

Q37394083-633E15A7-5C6A-4BC5-8A02-CEFE6DF5BC4F

Q37394083-6C30063A-8EE7-405B-AABF-3CDC3E7CA8A0

Q37394083-8B5D430C-085F-4241-9FD4-03623CD7031F

Q37394083-9616B461-5A4E-4539-B77F-F8DBC1DCF2EB

Q37394083-A2D1412D-35E6-49D7-864A-B630784BE8A1

Q37394083-ADB59F76-06B9-46F5-92E8-47EEDA6347F2

Q37394083-CD742F4D-1FB6-43A5-94C8-ECEFA18FDB36

Q37394083-EF5AAAA3-0519-4E89-A446-1BD158B04496

P2860

Q37394083-349C6037-7213-43E6-BDCD-FDFA01FD13D2

Q37394083-3A9E1946-7D69-4FB7-9558-E15937EFFD9B

Q37394083-52E74091-6DCF-4CE5-974D-F9F7B4D1CAD2

Q37394083-66DD4C52-3B1D-43B9-983B-79ECE59CB84B

Q37394083-711CECEA-1039-4A66-9649-2E413DC66BF3

Q37394083-716BC21E-4171-477D-8E6E-1648FD88F415

Q37394083-94949B24-DACB-49D6-B630-67267EE76013

Q37394083-CA4B3EAD-687F-4670-942B-36C3DEB05A88

Q37394083-CC084C0B-C833-45EE-9989-163773FC8031

Q37394083-DEF4FF36-C1C1-4909-B613-3DFA55C9371F

P304

Q37394083-FC18B7F1-8D9D-4630-994B-A5D38F583A1F

P31

Q37394083-E88A4449-E419-495C-9B60-E7249E8D7B00

P356

Q37394083-46063732-03CA-45AC-98A4-FD2C398F700A

P433

Q37394083-28469B74-A867-4863-A92A-A5BDBCF8A8CD

P478

Q37394083-B53F46F3-3C83-4AAB-871A-8E709FFCCD47

P50

Q37394083-45EA0172-EB9F-4F66-BD4B-9A9292A24EAC

Q37394083-8B647CA9-4B15-43E3-9F1E-EE2340F1D02C

P577

Q37394083-A559CCF6-2047-4DA4-B524-DEF43887337A

P698

Q37394083-82B3D6F2-A533-40C3-A840-42648DFF4BC5

P921

Q37394083-AEAA99DF-9C3B-496F-A22F-58A754DE8FDC

P932

Q37394083-B14D861C-B8CE-4A96-9E64-3345AF40CC21

P356

P1433

European Journal of Heart Failure

P1476

Efficacy of sacubitril/valsart ...... action: the PARADIGM-HF trial.

@en

P2093

Akshay S Desai

http://www.w3.org/2001/XMLSchema#string

Brian Claggett

http://www.w3.org/2001/XMLSchema#string

Jean Rouleau

http://www.w3.org/2001/XMLSchema#string

John R Teerlink

http://www.w3.org/2001/XMLSchema#string

Karl Swedberg

http://www.w3.org/2001/XMLSchema#string

Martin Lefkowitz

http://www.w3.org/2001/XMLSchema#string

Milton Packer

http://www.w3.org/2001/XMLSchema#string

Orly Vardeny

http://www.w3.org/2001/XMLSchema#string

Prospective Comparison of ARNI ...... re (PARADIGM-HF) Investigators

http://www.w3.org/2001/XMLSchema#string

Scott D Solomon

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin-neprilysin inhibition versus enalapril in heart failure

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial.

Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF.

Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure).

Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.

P304

1228-1234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJHF.580

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27283779

http://www.w3.org/2001/XMLSchema#string

P921

P932

5095784

http://www.w3.org/2001/XMLSchema#string